IBO
Impact Biomedical Inc
$
0.686
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.7189
Open
0.6984
VWAP
--
Vol
417.02K
Mkt Cap
8.29M
Low
0.672
Amount
--
EV/EBITDA(TTM)
--
Total Shares
12.09M
EV
19.32M
EV/OCF(TTM)
--
P/S(TTM)
--
Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
Show More
Valuation Metrics
The current forward P/E ratio for Impact Biomedical Inc (IBO.A) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Impact Biomedical Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+31.00%
-1.01M
Operating Profit
FY2025Q1
YoY :
+28.06%
-1.28M
Net Income after Tax
FY2025Q1
YoY :
+37.50%
-0.11
EPS - Diluted
FY2025Q1
-682.00K
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
88.0K
USD
2
3-6
Months
7.3M
USD
11
6-9
Months
17.1K
USD
4
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
310.0
USD
Months
6-9
2
4.0K
USD
Months
0-12
3
155.6K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
88.0K
USD
2
3-6
Months
7.3M
USD
11
6-9
Months
17.1K
USD
4
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
310.0
USD
Months
6-9
2
4.0K
USD
Months
0-12
3
155.6K
USD
Months
IBO News & Events
Events Timeline
2025-06-23 (ET)
2025-06-23
07:55:08
Impact BioMedical, Dr Ashleys enter strategic merger agreement
2025-02-26 (ET)
2025-02-26
08:40:42
Impact BioMedical announces acquisition of Celios in $1.15M equity transaction
2025-02-26
08:36:20
DSS announces sale of Celios to Impact BioMedical
Sign Up For More Events
Sign Up For More Events
News
9.5
06-25BenzingaWhy BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
9.0
06-24BenzingaWhy Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
8.5
06-23Yahoo FinanceTop Midday Gainers
Sign Up For More News
People Also Watch
MCVT
Mill City Ventures III Ltd
5.940
USD
+0.68%
ASPS
Altisource Portfolio Solutions SA
10.490
USD
-8.78%
MIGI
Mawson Infrastructure Group Inc
0.491
USD
-9.07%
LFWD
Lifeward Ltd
0.809
USD
+4.39%
SOHO
Sotherly Hotels Inc
0.854
USD
-2.73%
NCL
Northann Corp
0.185
USD
-4.65%
SLNH
Soluna Holdings Inc
0.500
USD
-7.07%
JFU
9F Inc
1.660
USD
+3.11%
GIGM
GigaMedia Ltd
1.450
USD
-0.68%
FAQ
What is Impact Biomedical Inc (IBO) stock price today?
The current price of IBO is 0.686 USD — it has decreased -2.14 % in the last trading day.
What is Impact Biomedical Inc (IBO)'s business?
What is the price predicton of IBO Stock?
What is Impact Biomedical Inc (IBO)'s revenue for the last quarter?
What is Impact Biomedical Inc (IBO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Impact Biomedical Inc (IBO)'s fundamentals?
How many employees does Impact Biomedical Inc (IBO). have?